Iron deficiency anaemia therapeutic - Fe3 Medical

Drug Profile

Iron deficiency anaemia therapeutic - Fe3 Medical

Latest Information Update: 08 Jul 2016

Price : $50

At a glance

  • Originator Fe3 Medical
  • Class Antianaemics; Iron compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Iron deficiency anaemia

Most Recent Events

  • 02 Mar 2016 Preclinical trials in Iron deficiency anaemia in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top